BE1006834A3 - Solution de perfusion, de conservation et de reperfusion d'organes. - Google Patents

Solution de perfusion, de conservation et de reperfusion d'organes. Download PDF

Info

Publication number: BE1006834A3
Authority: BE; Belgium
Prior art keywords: sep; solution; reperfusion; solutions; solutions according
Prior art date: 1990-11-20

Application number

BE9101067A

Other languages

English (en)

French (fr)

Inventor

Philippe Menasche

Original Assignee

Pasteur Merieux Serums Vacc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-11-20

Filing date

1991-11-19

Publication date

1995-01-03

1990-11-20 Priority claimed from FR9014424A external-priority patent/FR2669189B1/fr

1991-07-17 Priority claimed from FR9109027A external-priority patent/FR2679107B1/fr

1991-11-19 Application filed by Pasteur Merieux Serums Vacc filed Critical Pasteur Merieux Serums Vacc

1995-01-03 Application granted granted Critical

1995-01-03 Publication of BE1006834A3 publication Critical patent/BE1006834A3/fr

Links

230000010410 reperfusion Effects 0.000 title claims abstract description 44
238000001802 infusion Methods 0.000 title claims abstract description 30
210000000056 organ Anatomy 0.000 title claims abstract description 30
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 72
229960003180 glutathione Drugs 0.000 claims abstract description 33
108010024636 Glutathione Proteins 0.000 claims abstract description 24
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims abstract description 24
229960004308 acetylcysteine Drugs 0.000 claims abstract description 24
150000001875 compounds Chemical class 0.000 claims abstract description 21
239000001301 oxygen Substances 0.000 claims abstract description 19
229910052760 oxygen Inorganic materials 0.000 claims abstract description 19
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 17
238000004321 preservation Methods 0.000 claims abstract description 13
239000003963 antioxidant agent Substances 0.000 claims abstract description 7
239000002516 radical scavenger Substances 0.000 claims abstract description 7
230000003078 antioxidant effect Effects 0.000 claims abstract description 6
230000002829 reductive effect Effects 0.000 claims abstract description 5
229940123457 Free radical scavenger Drugs 0.000 claims abstract description 4
230000036961 partial effect Effects 0.000 claims abstract description 4
239000000243 solution Substances 0.000 claims description 96
150000003254 radicals Chemical class 0.000 claims description 13
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 10
229930195725 Mannitol Natural products 0.000 claims description 10
239000000594 mannitol Substances 0.000 claims description 10
235000010355 mannitol Nutrition 0.000 claims description 10
230000010412 perfusion Effects 0.000 claims description 10
239000003978 infusion fluid Substances 0.000 claims description 9
239000003761 preservation solution Substances 0.000 claims description 9
UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims description 7
230000015572 biosynthetic process Effects 0.000 claims description 7
239000000470 constituent Substances 0.000 claims description 7
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 6
206010030113 Oedema Diseases 0.000 claims description 6
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 6
239000011575 calcium Substances 0.000 claims description 6
230000000747 cardiac effect Effects 0.000 claims description 6
230000001413 cellular effect Effects 0.000 claims description 6
229960000958 deferoxamine Drugs 0.000 claims description 6
229930195712 glutamate Natural products 0.000 claims description 6
210000004185 liver Anatomy 0.000 claims description 6
230000002503 metabolic effect Effects 0.000 claims description 6
239000000203 mixture Substances 0.000 claims description 6
239000011591 potassium Substances 0.000 claims description 6
229910052700 potassium Inorganic materials 0.000 claims description 6
150000003573 thiols Chemical group 0.000 claims description 6
239000003795 chemical substances by application Substances 0.000 claims description 5
239000003112 inhibitor Substances 0.000 claims description 3
-1 oxygen radicals Chemical class 0.000 claims description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
229910052791 calcium Inorganic materials 0.000 claims description 2
230000004094 calcium homeostasis Effects 0.000 claims description 2
239000002738 chelating agent Substances 0.000 claims description 2
230000000670 limiting effect Effects 0.000 claims description 2
229910052751 metal Inorganic materials 0.000 claims description 2
239000002184 metal Substances 0.000 claims description 2
238000004806 packaging method and process Methods 0.000 claims description 2
238000004078 waterproofing Methods 0.000 claims description 2
238000009472 formulation Methods 0.000 claims 2
230000002401 inhibitory effect Effects 0.000 claims 1
238000001356 surgical procedure Methods 0.000 abstract 1
208000028867 ischemia Diseases 0.000 description 19
238000003860 storage Methods 0.000 description 16
230000000694 effects Effects 0.000 description 12
230000002861 ventricular Effects 0.000 description 9
230000002107 myocardial effect Effects 0.000 description 8
230000004087 circulation Effects 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
239000000126 substance Substances 0.000 description 7
241000700159 Rattus Species 0.000 description 6
230000006870 function Effects 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
230000001681 protective effect Effects 0.000 description 6
238000002054 transplantation Methods 0.000 description 6
230000006872 improvement Effects 0.000 description 5
239000011777 magnesium Substances 0.000 description 5
238000000034 method Methods 0.000 description 5
238000011084 recovery Methods 0.000 description 5
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
235000006708 antioxidants Nutrition 0.000 description 4
239000004033 plastic Substances 0.000 description 4
229920003023 plastic Polymers 0.000 description 4
238000012360 testing method Methods 0.000 description 4
208000010496 Heart Arrest Diseases 0.000 description 3
102000019197 Superoxide Dismutase Human genes 0.000 description 3
108010012715 Superoxide dismutase Proteins 0.000 description 3
230000008901 benefit Effects 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
102000016938 Catalase Human genes 0.000 description 2
108010053835 Catalase Proteins 0.000 description 2
102000003992 Peroxidases Human genes 0.000 description 2
206010063837 Reperfusion injury Diseases 0.000 description 2
229930003427 Vitamin E Natural products 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
230000035487 diastolic blood pressure Effects 0.000 description 2
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
210000004165 myocardium Anatomy 0.000 description 2
230000001590 oxidative effect Effects 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
238000011160 research Methods 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
235000019165 vitamin E Nutrition 0.000 description 2
229940046009 vitamin E Drugs 0.000 description 2
239000011709 vitamin E Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
241000153246 Anteros Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
241000282465 Canis Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
IEPRKVQEAMIZSS-UHFFFAOYSA-N Di-Et ester-Fumaric acid Natural products CCOC(=O)C=CC(=O)OCC IEPRKVQEAMIZSS-UHFFFAOYSA-N 0.000 description 1
IEPRKVQEAMIZSS-WAYWQWQTSA-N Diethyl maleate Chemical compound CCOC(=O)\C=C/C(=O)OCC IEPRKVQEAMIZSS-WAYWQWQTSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000001055 Ischemic Contracture Diseases 0.000 description 1
239000012839 Krebs-Henseleit buffer Substances 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
101100366137 Mesembryanthemum crystallinum SODCC.1 gene Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
101100096142 Panax ginseng SODCC gene Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
238000010165 Scheffé test Methods 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
108700042768 University of Wisconsin-lactobionate solution Proteins 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
229960003459 allopurinol Drugs 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
230000001964 calcium overload Effects 0.000 description 1
238000007675 cardiac surgery Methods 0.000 description 1
230000001101 cardioplegic effect Effects 0.000 description 1
239000008148 cardioplegic solution Substances 0.000 description 1
229940105657 catalase Drugs 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
239000002131 composite material Substances 0.000 description 1
230000008602 contraction Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
229940116901 diethyldithiocarbamate Drugs 0.000 description 1
LMBWSYZSUOEYSN-UHFFFAOYSA-N diethyldithiocarbamic acid Chemical compound CCN(CC)C(S)=S LMBWSYZSUOEYSN-UHFFFAOYSA-N 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000004217 heart function Effects 0.000 description 1
238000007654 immersion Methods 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
229940099584 lactobionate Drugs 0.000 description 1
JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
230000003902 lesion Effects 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
150000004701 malic acid derivatives Chemical class 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000004792 oxidative damage Effects 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229940072417 peroxidase Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000036313 post-ischemic recovery Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000001292 preischemic effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
230000003134 recirculating effect Effects 0.000 description 1
101150017120 sod gene Proteins 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
150000003890 succinate salts Chemical class 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
230000001550 time effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
208000003663 ventricular fibrillation Diseases 0.000 description 1
206010047302 ventricular tachycardia Diseases 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Environmental Sciences (AREA)
Zoology (AREA)
Dentistry (AREA)
Inorganic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

BE9101067A 1990-11-20 1991-11-19 Solution de perfusion, de conservation et de reperfusion d'organes. BE1006834A3 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9014424A FR2669189B1 (fr)	1990-11-20	1990-11-20	Solutions de perfusion et de stockage pour transplantations cardiaques.
FR9109027A FR2679107B1 (fr)	1991-07-17	1991-07-17	Solutions de perfusion, de conservation et de reperfusion d'organes.

Publications (1)

Publication Number	Publication Date
BE1006834A3 true BE1006834A3 (fr)	1995-01-03

Family

ID=26228338

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE9101067A BE1006834A3 (fr)	1990-11-20	1991-11-19	Solution de perfusion, de conservation et de reperfusion d'organes.

Country Status (8)

Country	Link
AT (1)	AT399440B (it)
BE (1)	BE1006834A3 (it)
CA (1)	CA2055827C (it)
CH (1)	CH683485A5 (it)
DE (1)	DE4138040A1 (it)
ES (1)	ES2050580B1 (it)
GB (1)	GB2249937B (it)
IT (1)	IT1251995B (it)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH686870A5 (fr) *	1992-09-18	1996-07-31	Pasteur Merieux Serums Vacc	Solution de perfusion, de conservation et de reperfusion d'organes.
EP0697169B1 (en) *	1993-05-07	2000-11-15	Chugai Seiyaku Kabushiki Kaisha	Organ preservative
DE4325547C2 (de) *	1993-07-29	1997-11-27	Max Planck Gesellschaft	Verwendung von Thiolverbindungen zur Therapie von Hepatitis-_Viren-induzierten Erkrankungen
JPH07215801A (ja) *	1994-01-28	1995-08-15	Senju Pharmaceut Co Ltd	肺保存剤および肺保存方法
JPH07330501A (ja) *	1994-06-14	1995-12-19	Senju Pharmaceut Co Ltd	肝保存剤および肝保存方法
DE4439477C2 (de) *	1994-11-08	1999-10-21	Asta Medica Ag	Verwendung von R,S-(+/-)-alpha-Liponsäure, R-(+)-alpha-Liponäure, S-(-)-alpha-Liponsäure in reduzierter oder oxidierter Form oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung der diabetischen Mikroangiopathie
DE19706111C2 (de) *	1997-02-17	1999-02-18	Fresenius Medical Care De Gmbh	Lösung zur Aufbewahrung von Organen
US5990153A (en) *	1997-05-05	1999-11-23	Wood; John G.	Ultrasonicated α-lipoic acid solutions for attenuating microvascular injury
US6045990A (en) *	1998-07-09	2000-04-04	Baust; John M.	Inclusion of apoptotic regulators in solutions for cell storage at low temperature
DE19834087C1 (de) *	1998-07-29	2000-03-30	Mirzaie Sedaposhteh Massoud	Wäßrige Konservierungslösung und Verfahren zur Aufbewahrung tierischen Gewebes
GB0028414D0 (en)	2000-11-22	2001-01-03	Univ Leeds	Flush preservation solution
DE102007026392A1 (de)	2007-06-06	2008-12-11	Bayer Healthcare Ag	Lösungen für die Perfusion und Konservierung von Organen und Geweben
GR20180100514A (el) *	2018-11-07	2020-06-15	Πανεπιστημιο Πατρων	Φαρμακευτικοι συνδυασμοι και κιτ για την προληψη ή την θεραπεια του πονου και αλλων επιπλοκων της ορθοπαιδικης ή αγγειακης χειρουργικης και του πολλαπλου τραυματος

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1987001940A1 (en) *	1985-10-03	1987-04-09	Wisconsin Alumni Research Foundation	Perfusate for the preservation of organs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4186253A (en) *	1978-10-10	1980-01-29	The Green Cross Corporation	Perfusate for preserving organ to be transplanted and preserving method
US4473552A (en) *	1981-03-16	1984-09-25	Jost Leonora I	Anaerobic method for preserving whole blood, tissue and components containing living mammalian cells
US4423600A (en) *	1982-12-10	1984-01-03	Mckenna Joan J	Method for preservation of living organic tissue by freezing
SE8403912D0 (sv) *	1984-07-30	1984-07-30	Pharmacia Ab	Lekemedelssats eller -komposition
DE3581407D1 (de) *	1985-09-06	1991-02-21	Nestle Sa	Bewahrung lebender gewebe.
US4879283A (en) *	1985-10-03	1989-11-07	Wisconsin Alumni Research Foundation	Solution for the preservation of organs
ES2007994A6 (es) *	1988-08-16	1989-07-01	Grino Boira Jose Maria	Medio liquido para perfusion y preservacion de organos.
US4920044A (en) *	1988-11-08	1990-04-24	The Cleveland Clinic Foundation	Intracellular flush solution for preserving organs
US4938961A (en) *	1989-04-28	1990-07-03	Geoffrey Collins	Organ preservation solution containing pokyethylene gycol and method of performing cardioplegia

1991
- 1991-11-05 CH CH3224/91A patent/CH683485A5/fr not_active IP Right Cessation
- 1991-11-11 IT ITMI912991A patent/IT1251995B/it active IP Right Grant
- 1991-11-18 GB GB9124488A patent/GB2249937B/en not_active Expired - Lifetime
- 1991-11-18 AT AT0228791A patent/AT399440B/de not_active IP Right Cessation
- 1991-11-18 ES ES09102549A patent/ES2050580B1/es not_active Expired - Fee Related
- 1991-11-19 BE BE9101067A patent/BE1006834A3/fr not_active IP Right Cessation
- 1991-11-19 CA CA002055827A patent/CA2055827C/en not_active Expired - Lifetime
- 1991-11-19 DE DE4138040A patent/DE4138040A1/de not_active Withdrawn

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1987001940A1 (en) *	1985-10-03	1987-04-09	Wisconsin Alumni Research Foundation	Perfusate for the preservation of organs

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A.BLAUSTEIN ET. AL.: "Myocardial glutathione depletion impairs recovery after short periods of ischemia", CIRCULATION, vol. 80, no. 5, October 1989 (1989-10-01), pages 1449 - 1457 *
C.CECONI ET. AL.: "The role of glutathione status in the protection against ischaemic and reperfusion damage: effects of N-acetylcysteine", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, vol. 20, no. 1, January 1988 (1988-01-01), LONDRES,GB, pages 5 - 13 *
H.TANIGUCHI: "Experimental study on active oxygen species to warm ischaemic lung: Availability of GSH, SOD and allopurinol", ACTA MEDICA NAGASAKI, vol. 34, no. 2-4, 1989, pages 177 - 187 *
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, vol. 22, suppl. V, 1990, abrégé no. P82, Academic Press, Londres, GB; W.N.WICOMB et. al.: *
M.BERNIER ET AL.: "Reperfusion-induced arrhythmias and oxygen-derived free radicals. Studies with", CIRCULATION RESEARCH, vol. 58, no. 3, March 1988 (1988-03-01), pages 331 - 340 *

Also Published As

Publication number	Publication date
ITMI912991A0 (it)	1991-11-11
AT399440B (de)	1995-05-26
ITMI912991A1 (it)	1993-05-11
CA2055827A1 (en)	1992-05-21
GB9124488D0 (en)	1992-01-08
IT1251995B (it)	1995-05-27
GB2249937A (en)	1992-05-27
GB2249937B (en)	1994-02-16
CA2055827C (en)	1999-06-15
DE4138040A1 (de)	1992-05-21
ATA228791A (de)	1994-10-15
ES2050580B1 (es)	1994-12-16
ES2050580A1 (es)	1994-05-16
CH683485A5 (fr)	1994-03-31

Legal Events

Date	Code	Title	Description
2007-12-31	RE	Patent lapsed	Effective date: 20061130

Publication	Publication Date	Title
US5498427A (en)	1996-03-12	Solutions for the perfusion, preservation and reperfusion of organs
BE1006834A3 (fr)	1995-01-03	Solution de perfusion, de conservation et de reperfusion d'organes.
YTREHUS et al.	1986	Influence of oxygen radicals generated by xanthine oxidase in the isolated perfused rat heart
Southard	1999	Organ preservation
Menasche et al.	1994	Experimental evaluation of Celsior [R] a new heart preservation solution
Rabl et al.	1993	A multivitamin infusion prevents lipid peroxidation and improves transplantation performance
US5145771A (en)	1992-09-08	Rinse solution for organs and tissues
RU2161405C2 (ru)	2001-01-10	Растворы для трансплантатов органов и способ трансплантации органа
US5552267A (en)	1996-09-03	Solution for prolonged organ preservation
US9029078B2 (en)	2015-05-12	Perfusion and/or preservation solution for organs
BE1007500A3 (fr)	1995-07-18	Solution de perfusion, de conservation et de reperfusion d'organes.
US20020132220A1 (en)	2002-09-19	Use of selectin antagonists in organ preservation solutions
JP3326177B2 (ja)	2002-09-17	臓器保存液
US9462803B2 (en)	2016-10-11	Organ preservation and/or perfusion
CA2207324A1 (en)	1996-06-20	Organ transplant solutions and method for transplanting an organ
Sumimoto et al.	1987	Ischemic damage prevention by coenzyme Q10 treatment of the donor before orthotopic liver transplantation: Biochemical and histologic findings
Okboy et al.	1992	The effect of iloprost and NDGA in ischemia reperfusion injury in rat liver
FR2679107A1 (fr)	1993-01-22	Solutions de perfusion, de conservation et de reperfusion d'organes.
Marshall	1997	Preservation by simple hypothermia
Keith	1993	Oxygen free radicals in cardiac transplantation
FR2669189A1 (fr)	1992-05-22	Solutions de perfusion et de stockage pour transplantations cardiaques.
Christie et al.	1993	Lung preservation
KR100304594B1 (ko)	2001-09-13	이식용 장기 및 혈액세포 보존제의 조성물
Sun et al.	1992	Superoxide dismutase: enhanced small intestinal preservation
FR2723818A1 (fr)	1996-03-01	Composition de perfusion pour ameliorer la conservation d'organes vivants